CX717, a low-impact ampakine, is a positive allosteric modulator of AMPA-glutamate receptors. This clinical study evaluated CX717 for the treatment of ADHD symptomology in a randomized, double-blind, placebo-controlled, multi-center, 2-period crossover with two doses of CX717 (200 or 800 mg BID). Each treatment period lasted 3 weeks with a 2-week washout. Subjects met DSM-IV criteria for adult ADHD and had moderate to severe symptoms. The primary efficacy measure was the change from baseline on…
